Efficacy of IntraCoronary Erythropoietin Delivery BEfore Reperfusion-Gauging Infarct Size in Patients with Acute ST-segment Elevation Myocardial Infarction (ICEBERG)
Previous clinical studies have shown inconsistent results regarding the effect of erythropoietin in ST-segment elevation myocardial infarction (STEMI). This study investigated whether directed intracoronary infusion of darbepoetin-α into ischemic myocardium before reperfusion would reduce infarct si...
Saved in:
| Published in: | International Heart Journal Vol. 60; no. 2; pp. 255 - 263 |
|---|---|
| Main Authors: | , , , , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
Japan
International Heart Journal Association
30-03-2019
Japan Science and Technology Agency |
| Subjects: | |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | Previous clinical studies have shown inconsistent results regarding the effect of erythropoietin in ST-segment elevation myocardial infarction (STEMI). This study investigated whether directed intracoronary infusion of darbepoetin-α into ischemic myocardium before reperfusion would reduce infarct size or post-infarct remodeling in STEMI patients.Eighty STEMI patients received one of the following treatments simultaneously with the first balloon inflation: intracoronary darbepoetin-α 300 μg (n = 40) or saline (n = 40), administered via the over-the-wire balloon system. The primary endpoint was infarct size estimated by serial cardiac enzyme levels after procedure. The secondary endpoints were (1) infarct size and proportion of salvaged myocardium measured with cardiac magnetic resonance (CMR) at baseline; (2) post-infarct remodeling (PIR), defined as an increase in left ventricular end-diastolic volume more than 20% at 4 months compared to the baseline on CMR; and (3) composite cardiovascular endpoints assessed at 4 months.The peak CK-MB [median 270.0 (interquartile range 139.8-356.3) versus 231.5 (131.0-408.5) ng/mL, P = 0.55] and troponin-I [128.5 (63.5-227.8) versus 109.0 (43.8-220.0) ng/mL, P = 0.52) ] did not differ between the darbepoetin-α and control group. Fifty-seven patients completed the baseline and 4-month follow-up CMR. There were no differences in infarct size [30.6 (18.1-49.8) versus 31.5 (22.5-47.3) cm3, P = 0.91), proportion of salvaged myocardium [26.7% (15.9-42.6%) versus 35.8% (22.4-48.8%), P = 0.12) or PIR (8.0% versus 6.7%, P = 0.62) between the two groups. Composite cardiovascular outcomes did not differ between the two groups.In conclusion, administration of intracoronary darbepoetin-α before reperfusion did not reduce infarct size or post-infarct remodeling in STEMI patients. |
|---|---|
| AbstractList | Previous clinical studies have shown inconsistent results regarding the effect of erythropoietin in ST-segment elevation myocardial infarction (STEMI). This study investigated whether directed intracoronary infusion of darbepoetin-α into ischemic myocardium before reperfusion would reduce infarct size or post-infarct remodeling in STEMI patients. Eighty STEMI patients received one of the following treatments simultaneously with the first balloon inflation: intracoronary darbepoetin-α 300 μg (n = 40) or saline (n = 40), administered via the over-the-wire balloon system. The primary endpoint was infarct size estimated by serial cardiac enzyme levels after procedure. The secondary endpoints were (1) infarct size and proportion of salvaged myocardium measured with cardiac magnetic resonance (CMR) at baseline; (2) post-infarct remodeling (PIR), defined as an increase in left ventricular end-diastolic volume more than 20% at 4 months compared to the baseline on CMR; and (3) composite cardiovascular endpoints assessed at 4 months. The peak CK-MB [median 270.0 (interquartile range 139.8-356.3) versus 231.5 (131.0-408.5) ng/mL, P = 0.55] and troponin-I [128.5 (63.5-227.8) versus 109.0 (43.8-220.0) ng/mL, P = 0.52) ] did not differ between the darbepoetin-α and control group. Fifty-seven patients completed the baseline and 4-month follow-up CMR. There were no differences in infarct size [30.6 (18.1-49.8) versus 31.5 (22.5-47.3) cm3, P = 0.91), proportion of salvaged myocardium [26.7% (15.9-42.6%) versus 35.8% (22.4-48.8%), P = 0.12) or PIR (8.0% versus 6.7%, P = 0.62) between the two groups. Composite cardiovascular outcomes did not differ between the two groups. In conclusion, administration of intracoronary darbepoetin-α before reperfusion did not reduce infarct size or post-infarct remodeling in STEMI patients. Previous clinical studies have shown inconsistent results regarding the effect of erythropoietin in ST-segment elevation myocardial infarction (STEMI). This study investigated whether directed intracoronary infusion of darbepoetin-α into ischemic myocardium before reperfusion would reduce infarct size or post-infarct remodeling in STEMI patients.Eighty STEMI patients received one of the following treatments simultaneously with the first balloon inflation: intracoronary darbepoetin-α 300 μg (n = 40) or saline (n = 40), administered via the over-the-wire balloon system. The primary endpoint was infarct size estimated by serial cardiac enzyme levels after procedure. The secondary endpoints were (1) infarct size and proportion of salvaged myocardium measured with cardiac magnetic resonance (CMR) at baseline; (2) post-infarct remodeling (PIR), defined as an increase in left ventricular end-diastolic volume more than 20% at 4 months compared to the baseline on CMR; and (3) composite cardiovascular endpoints assessed at 4 months.The peak CK-MB [median 270.0 (interquartile range 139.8-356.3) versus 231.5 (131.0-408.5) ng/mL, P = 0.55] and troponin-I [128.5 (63.5-227.8) versus 109.0 (43.8-220.0) ng/mL, P = 0.52) ] did not differ between the darbepoetin-α and control group. Fifty-seven patients completed the baseline and 4-month follow-up CMR. There were no differences in infarct size [30.6 (18.1-49.8) versus 31.5 (22.5-47.3) cm , P = 0.91), proportion of salvaged myocardium [26.7% (15.9-42.6%) versus 35.8% (22.4-48.8%), P = 0.12) or PIR (8.0% versus 6.7%, P = 0.62) between the two groups. Composite cardiovascular outcomes did not differ between the two groups.In conclusion, administration of intracoronary darbepoetin-α before reperfusion did not reduce infarct size or post-infarct remodeling in STEMI patients. |
| Author | Seo, Won-Woo Suh, Jung-Won Youn, Tae-Jin Cho, Young-Seok Choi, Dong-Ju Oh, Il-Young Chae, In-Ho Yoon, Chang-Hwan |
| Author_xml | – sequence: 1 fullname: Seo, Won-Woo organization: Division of Cardiology, Department of Internal Medicine, Kangdong Sacred Heart Hospital – sequence: 2 fullname: Suh, Jung-Won organization: Department of Internal Medicine, Seoul National University College of Medicine, Cardiovascular Center, Seoul National University Bundang Hospital – sequence: 3 fullname: Oh, Il-Young organization: Department of Internal Medicine, Seoul National University College of Medicine, Cardiovascular Center, Seoul National University Bundang Hospital – sequence: 4 fullname: Yoon, Chang-Hwan organization: Department of Internal Medicine, Seoul National University College of Medicine, Cardiovascular Center, Seoul National University Bundang Hospital – sequence: 5 fullname: Cho, Young-Seok organization: Department of Internal Medicine, Seoul National University College of Medicine, Cardiovascular Center, Seoul National University Bundang Hospital – sequence: 6 fullname: Youn, Tae-Jin organization: Department of Internal Medicine, Seoul National University College of Medicine, Cardiovascular Center, Seoul National University Bundang Hospital – sequence: 7 fullname: Chae, In-Ho organization: Department of Internal Medicine, Seoul National University College of Medicine, Cardiovascular Center, Seoul National University Bundang Hospital – sequence: 8 fullname: Choi, Dong-Ju organization: Department of Internal Medicine, Seoul National University College of Medicine, Cardiovascular Center, Seoul National University Bundang Hospital |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/30799375$$D View this record in MEDLINE/PubMed |
| BookMark | eNo9kd1u0zAYhi00xH7ghAtAljgBpAz_JE5yxtaFUmkItI1jy3E-t65au9jOpnI_3Ccu7XpiW68fP5_k9xydOO8AobeUXNKKi892sbykTUF49QKdUV62BWdte3I4My6qU3Qe45KQklakfoVOOanbltfVGfrbGWO10lvsDZ65FNTEB-9U2OIubNMi-I23kKzDN7Cyj5Dz6874APgONhDMGK13xVSNc-vmWWBU0Anf2z-A85ufKllwKeInmxb4So8J8P1DEWG-zjHuVvCYCe_w963XKgxWrZ4du_TDbNJdd3fTj6_RS6NWEd4c9gv062v3MPlW3P6YziZXt4Uu2yYVQkPLjBCk71XFGlDQaGW0Ai0IGIChNm0NolJsaGra19DWZdmwgRJVDbqv-AV6v_dugv89Qkxy6cfg8kjJGCeCipqJTH3aUzr4GAMYuQl2nb9MUiJ3jcjciKSNzI1k-N1BOfZrGI7ocwUZ-LIHljGpORwBFZLVK_jvEkSy3bJ3Hq_0QgUJjv8DOSGjAQ |
| CitedBy_id | crossref_primary_10_29001_2073_8552_2023_38_2_51_56 crossref_primary_10_1536_ihj_19_384 crossref_primary_10_1016_j_colsurfb_2020_111012 crossref_primary_10_2174_1570161120666220819163025 crossref_primary_10_1111_jcmm_15611 crossref_primary_10_7759_cureus_25671 crossref_primary_10_1038_s41392_022_00925_z crossref_primary_10_2174_1381612826666200219095548 crossref_primary_10_36660_ijcs_20200226 |
| Cites_doi | 10.1161/01.CIR.0000127954.98131.23 10.1016/0735-1097(94)90292-5 10.1016/j.cardiores.2003.10.011 10.1536/ihj.16-391 10.1007/s10557-005-3189-6 10.1016/j.jcmg.2009.02.011 10.1161/01.CIR.101.25.2981 10.1161/CIRCINTERVENTIONS.109.904425 10.1001/jama.2011.592 10.1016/j.tips.2008.02.002 10.1254/jphs.FP0050966 10.1016/0022-2828(73)90030-8 10.1016/j.amjcard.2009.05.050 10.1007/s10557-006-7680-5 10.1016/j.ijcard.2010.02.002 10.1007/s10557-013-6461-1 10.1016/j.ijcard.2009.10.028 10.4330/wjc.v6.i3.100 10.1345/aph.1A416 10.1038/sj.ki.5001546 10.1007/s00228-011-1160-y 10.1016/j.jacc.2005.03.044 10.1016/j.cardiores.2004.11.019 10.1161/01.CIR.0000078635.89229.8A 10.1016/j.jacc.2006.04.008 10.1007/s40256-013-0042-3 10.1161/01.CIR.97.23.2302 10.1016/j.ahj.2012.07.031 10.1056/NEJMra071667 10.1093/eurheartj/ehq304 10.1016/j.cct.2013.03.001 10.1016/j.ijcard.2012.05.029 10.1038/nrcardio.2012.36 10.1152/physrev.1992.72.2.449 10.1536/ihj.16-448 10.1007/s10557-013-6470-0 10.1592/phco.27.4.535 10.1536/ihj.17-114 10.1016/S0022-2828(05)82390-9 10.1016/j.acvd.2012.12.001 |
| ContentType | Journal Article |
| Copyright | 2019 by the International Heart Journal Association Copyright Japan Science and Technology Agency 2019 |
| Copyright_xml | – notice: 2019 by the International Heart Journal Association – notice: Copyright Japan Science and Technology Agency 2019 |
| DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 7QP |
| DOI | 10.1536/ihj.18-035 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef Calcium & Calcified Tissue Abstracts |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef Calcium & Calcified Tissue Abstracts |
| DatabaseTitleList | Calcium & Calcified Tissue Abstracts MEDLINE |
| Database_xml | – sequence: 1 dbid: ECM name: MEDLINE url: https://search.ebscohost.com/login.aspx?direct=true&db=cmedm&site=ehost-live sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1349-3299 |
| EndPage | 263 |
| ExternalDocumentID | 10_1536_ihj_18_035 30799375 article_ihj_60_2_60_18_035_article_char_en |
| Genre | Randomized Controlled Trial Clinical Trial, Phase II Journal Article |
| GroupedDBID | --- .55 29J 2WC 53G 5GY ACPRK ADBBV AENEX ALMA_UNASSIGNED_HOLDINGS BAWUL CS3 DIK DU5 E3Z EBS EJD F5P GX1 JSF JSH KQ8 OK1 RJT RZJ SDH TR2 X7M CGR CUY CVF ECM EIF NPM AAYXX CITATION 7QP |
| ID | FETCH-LOGICAL-c498t-6ce92f660bba528eae8cafcaec60efeed7f97e65a2d871b7e974482d10a5dcb53 |
| ISSN | 1349-2365 |
| IngestDate | Thu Oct 10 19:37:29 EDT 2024 Fri Aug 23 03:31:31 EDT 2024 Wed Oct 16 00:50:15 EDT 2024 Wed Apr 05 07:40:49 EDT 2023 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 2 |
| Keywords | Left ventricle remodeling Darbepoetin alfa |
| Language | English |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c498t-6ce92f660bba528eae8cafcaec60efeed7f97e65a2d871b7e974482d10a5dcb53 |
| OpenAccessLink | https://www.jstage.jst.go.jp/article/ihj/60/2/60_18-035/_article/-char/en |
| PMID | 30799375 |
| PQID | 2230616726 |
| PQPubID | 2048496 |
| PageCount | 9 |
| ParticipantIDs | proquest_journals_2230616726 crossref_primary_10_1536_ihj_18_035 pubmed_primary_30799375 jstage_primary_article_ihj_60_2_60_18_035_article_char_en |
| PublicationCentury | 2000 |
| PublicationDate | 2019/03/30 |
| PublicationDateYYYYMMDD | 2019-03-30 |
| PublicationDate_xml | – month: 03 year: 2019 text: 2019/03/30 day: 30 |
| PublicationDecade | 2010 |
| PublicationPlace | Japan |
| PublicationPlace_xml | – name: Japan – name: Tokyo |
| PublicationTitle | International Heart Journal |
| PublicationTitleAlternate | Int. Heart J. |
| PublicationYear | 2019 |
| Publisher | International Heart Journal Association Japan Science and Technology Agency |
| Publisher_xml | – name: International Heart Journal Association – name: Japan Science and Technology Agency |
| References | 32. Hirata A, Minamino T, Asanuma H, et al. Erythropoietin enhances neovascularization of ischemic myocardium and improves left ventricular dysfunction after myocardial infarction in dogs. J Am Coll Cardiol 2006; 48: 176-84. 12. Ott I, Schulz S, Mehilli J, et al. Erythropoietin in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention a randomized, double-blind trial. Circ Cardiovasc Interv 2010; 3: 408-13. 15. Lim GB. Antiplatelet therapy: Intracoronary abciximab during pci for STEMI. Nat Rev Cardiol 2012; 9: 258. 26. Wright J, Adriaenssens T, Dymarkowski S, Desmet W, Bogaert J. Quantification of myocardial area at risk with T2-weighted CMR: Comparison with contrast-enhanced CMR and coronary angiography. JACC Cardiovasc Imaging 2009; 2: 825-31. 28. Brines M, Cerami A. Discovering erythropoietin's extra-hematopoietic functions: Biology and clinical promise. Kidney Int 2006; 70: 246-50. 11. Binbrek AS, Rao NS, Al Khaja N, Assaqqaf J, Sobel BE. Erythropoietin to augment myocardial salvage induced by coronary thrombolysis in patients with ST-segment elevation acute myocardial infarction. Am J Cardiol 2009; 104: 1035-40. 13. Joy MS. Darbepoetin alfa: A novel erythropoiesis-stimulating protein. Ann Pharmacother 2002; 36: 1183-92. 8. Suh JW, Chung WY, Kim YS, et al. The effect of intravenous administration of erythropoietin on the infarct size in primary percutaneous coronary intervention. Int J Cardiol 2011; 149: 216-20. 20. van't Hof AW, Liem A, Suryapranata H, Hoorntje JC, de Boer M-J, Zijlstra F. Angiographic assessment of myocardial reperfusion in patients treated with primary angioplasty for acute myocardial infarction: Myocardial blush grade. Circulation 1998; 97: 2302-6. 18. Li J, Xu H, Gao Q, Wen Y. Effect of erythropoiesis-stimulating agents in acute ST-segment elevation myocardial infarction: A systematic review. Eur J Clin Pharmacol 2012; 68: 469-77. 24. Sutton MG, Sharpe N. Left ventricular remodeling after myocardial infarction: Pathophysiology and therapy. Circulation 2000; 101: 2981-8. 27. Jelkmann W. Erythropoietin: Structure, control of production, and function. Physiol Rev 1992; 72: 449-89. 21. Kim D-W, Her S-H, Park M-W, et al. Impact of postprocedural TIMI flow on long-term clinical outcomes in patients with acute myocardial infarction. Int Heart J 2017; 58: 674-85. 41. Wen Y, Xu J, Ma X, Gao Q. High-dose erythropoietin in acute ST-segment elevation myocardial infarction: A meta-analysis of randomized controlled trials. Am J Cardiovasc Drugs 2013; 13: 435-42. 7. van der Meer P, Lipsic E, Henning RH, et al. Erythropoietin induces neovascularization and improves cardiac function in rats with heart failure after myocardial infarction. J Am Coll Cardiol 2005; 46: 125-33. 9. Ferrario M, Arbustini E, Massa M, et al. High-dose erythropoietin in patients with acute myocardial infarction: A pilot, randomised, placebo-controlled study. Int J Cardiol 2011; 147: 124-31. 25. Yoon CH, Chung WY, Suh JW, et al. Distal protection device aggravated microvascular obstruction evaluated by cardiac MR after primary percutaneous intervention for ST-elevation myocardial infarction. Int J Cardiol 2013; 167: 2002-7. 39. Sutton MG, Sharpe N. Left ventricular remodeling after myocardial infarction. Circulation 2000; 101: 2981-8. 33. Riksen NP, Hausenloy DJ, Yellon DM. Erythropoietin: Ready for prime-time cardioprotection. Trends Pharmacol Sci 2008; 29: 258-67. 3. Fukui Y, Nozawa T, Ihori H, et al. Nicorandil attenuates ischemia-reperfusion injury via inhibition of norepinephrine release from cardiac sympathetic nerve terminals. Int Heart J 2017; 58: 787-93. 5. Cai Z, Manalo DJ, Wei G, et al. Hearts from rodents exposed to intermittent hypoxia or erythropoietin are protected against ischemia-reperfusion injury. Circulation 2003; 108: 79-85. 2. Dominguez-Rodriguez A, Abreu-Gonzalez P, Reiter RJ. Cardioprotection and pharmacological therapies in acute myocardial infarction: Challenges in the current era. World J Cardiol 2014; 6: 100-6. 1. Yellon DM, Hausenloy DJ. Myocardial reperfusion injury. N Engl J Med 2007; 357: 1121-35. 31. Vinten-Johansen J. Involvement of neutrophils in the pathogenesis of lethal myocardial reperfusion injury. Cardiovasc Res 2004; 61: 481-97. 10. Voors AA, Belonje AM, Zijlstra F, et al. A single dose of erythropoietin in ST-elevation myocardial infarction. Eur Heart J 2010; 31: 2593-600. 34. Najjar SS, Rao SV, Melloni C, et al. Intravenous erythropoietin in patients with ST-segment elevation myocardial infarction: Reveal: A randomized controlled trial. JAMA 2011; 305: 1863-72. 36. Gao D, Ning N, Niu X, et al. Erythropoietin treatment in patients with acute myocardial infarction: A meta-analysis of randomized controlled trials. Am Heart J 2012; 164: 715-27.e711. 37. Roubille F, Prunier F, Barrère-Lemaire S, et al. What is the role of erythropoietin in acute myocardial infarct? Bridging the gap between experimental models and clinical trials. Cardiovasc Drugs Ther 2013; 27: 315. 29. Cai Z, Semenza GL. Phosphatidylinositol-3-kinase signaling is required for erythropoietin-mediated acute protection against myocardial ischemia/reperfusion injury. Circulation 2004; 109: 2050-3. 35. Ott I, Schulz S, Mehilli J, et al. Erythropoietin in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary interventionclinical perspective: A randomized, double-blind trial. Circ Cardiovasc Interv 2010; 3: 408-13. 40. Nishiya D, Omura T, Shimada K, et al. Effects of erythropoietin on cardiac remodeling after myocardial infarction. J Pharmacol Sci 2006; 101: 31-9. 19. Moon C, Krawczyk M, Paik D, Lakatta EG, Talan MI. Cardioprotection by recombinant human erythropoietin following acute experimental myocardial infarction: Dose response and therapeutic window. Cardiovasc Drugs Ther 2005; 19: 243-50. 6. Rui T, Feng Q, Lei M, et al. Erythropoietin prevents the acute myocardial inflammatory response induced by ischemia/reperfusion via induction of ap-1. Cardiovasc Res 2005; 65: 719-27. 14. Voils SA, Harpe SH, Brophy GM. Comparison of darbepoetin alfa and epoetin alfa in the management of anemia of critical illness. Pharmacotherapy 2007; 27: 535-41. 17. Lipšic E, van der Meer P, Voors AA, et al. A single bolus of a long-acting erythropoietin analogue darbepoetin alfa in patients with acute myocardial infarction: A randomized feasibility and safety study. Cardiovasc Drugs Ther 2006; 20: 135-41. 42. Fokkema ML, Kleijn L, van der Meer P, et al. Long term effects of epoetin alfa in patients with ST-elevation myocardial infarction. Cardiovasc Drugs Ther 2013; 27: 433-9. 30. Hearse D, Humphrey S, Chain E. Abrupt reoxygenation of the anoxic potassium-arrested perfused rat heart: A study of myocardial enzyme release. J Mol Cell Cardiol 1973; 5: 395-407. 16. Suh JW, Yoon YE, Oh IY, et al. A single-center prospective randomized controlled trial evaluating the safety and efficacy of intracoronary erythropoietin delivery before reperfusion: Gauging infarct size in patients with acute ST-segment elevation myocardial infarction. Study design and rationale of the 'ICEBERG Trial'. Contemp Clin Trials 2013; 35: 145-50. 38. Roubille F, Micheau A, Combes S, et al. Intracoronary administration of darbepoetin-alpha at onset of reperfusion in acute myocardial infarction: Results of the randomized Intra-Co-EpoMI trial. Arch Cardiovasc Dis 2013; 106: 135-45. 23. Cleutjens JP, Kandala JC, Guarda E, Guntaka RV, Weber KT. Regulation of collagen degradation in the rat myocardium after infarction. J Mol Cell Cardiol 1995; 27: 1281-92. 4. Wang Y, Wang Q, Yu W, Du H. Crocin attenuates oxidative stress and myocardial infarction injury in rats. Int Heart J 2018; 59: 387-93. 22. Schröder R, Dissmann R, Brüggemann T, et al. Extent of early ST segment elevation resolution: A simple but strong predictor of outcome in patients with acute myocardial infarction. J Am Coll Cardiol 1994; 24: 384-91. 22 23 24 25 26 27 28 29 30 31 10 32 11 33 12 34 13 35 14 36 15 37 16 38 17 39 18 19 1 2 3 4 5 6 7 8 9 40 41 20 21 |
| References_xml | – ident: 28 doi: 10.1161/01.CIR.0000127954.98131.23 – ident: 22 doi: 10.1016/0735-1097(94)90292-5 – ident: 30 doi: 10.1016/j.cardiores.2003.10.011 – ident: 3 doi: 10.1536/ihj.16-391 – ident: 19 doi: 10.1007/s10557-005-3189-6 – ident: 25 doi: 10.1016/j.jcmg.2009.02.011 – ident: 38 doi: 10.1161/01.CIR.101.25.2981 – ident: 12 doi: 10.1161/CIRCINTERVENTIONS.109.904425 – ident: 33 doi: 10.1001/jama.2011.592 – ident: 32 doi: 10.1016/j.tips.2008.02.002 – ident: 39 doi: 10.1254/jphs.FP0050966 – ident: 29 doi: 10.1016/0022-2828(73)90030-8 – ident: 11 doi: 10.1016/j.amjcard.2009.05.050 – ident: 17 doi: 10.1007/s10557-006-7680-5 – ident: 8 doi: 10.1016/j.ijcard.2010.02.002 – ident: 34 doi: 10.1161/CIRCINTERVENTIONS.109.904425 – ident: 36 doi: 10.1007/s10557-013-6461-1 – ident: 9 doi: 10.1016/j.ijcard.2009.10.028 – ident: 2 doi: 10.4330/wjc.v6.i3.100 – ident: 13 doi: 10.1345/aph.1A416 – ident: 27 doi: 10.1038/sj.ki.5001546 – ident: 18 doi: 10.1007/s00228-011-1160-y – ident: 7 doi: 10.1016/j.jacc.2005.03.044 – ident: 6 doi: 10.1016/j.cardiores.2004.11.019 – ident: 5 doi: 10.1161/01.CIR.0000078635.89229.8A – ident: 31 doi: 10.1016/j.jacc.2006.04.008 – ident: 40 doi: 10.1007/s40256-013-0042-3 – ident: 20 doi: 10.1161/01.CIR.97.23.2302 – ident: 35 doi: 10.1016/j.ahj.2012.07.031 – ident: 1 doi: 10.1056/NEJMra071667 – ident: 10 doi: 10.1093/eurheartj/ehq304 – ident: 16 doi: 10.1016/j.cct.2013.03.001 – ident: 24 doi: 10.1016/j.ijcard.2012.05.029 – ident: 15 doi: 10.1038/nrcardio.2012.36 – ident: 26 doi: 10.1152/physrev.1992.72.2.449 – ident: 21 doi: 10.1536/ihj.16-448 – ident: 41 doi: 10.1007/s10557-013-6470-0 – ident: 14 doi: 10.1592/phco.27.4.535 – ident: 4 doi: 10.1536/ihj.17-114 – ident: 23 doi: 10.1016/S0022-2828(05)82390-9 – ident: 37 doi: 10.1016/j.acvd.2012.12.001 |
| SSID | ssj0041507 |
| Score | 2.2594507 |
| Snippet | Previous clinical studies have shown inconsistent results regarding the effect of erythropoietin in ST-segment elevation myocardial infarction (STEMI). This... |
| SourceID | proquest crossref pubmed jstage |
| SourceType | Aggregation Database Index Database Publisher |
| StartPage | 255 |
| SubjectTerms | Aged Angioplasty, Balloon, Coronary - methods Balloon treatment Calcium-binding protein Coronary Vessels Darbepoetin alfa Darbepoetin alfa - administration & dosage Darbepoetin alfa - adverse effects Drug Monitoring - methods Electrocardiography Erythropoietin Female Heart Heart attacks Hematinics - administration & dosage Hematinics - adverse effects Humans Infusions, Intra-Arterial Ischemia Left ventricle remodeling Magnetic Resonance Imaging, Cine - methods Male Middle Aged Myocardial infarction Myocardium Myocardium - pathology Preoperative Care - methods Reperfusion ST Elevation Myocardial Infarction - diagnosis ST Elevation Myocardial Infarction - therapy Stroke Volume - drug effects Treatment Outcome Troponin Ventricle Ventricular Remodeling - drug effects |
| Title | Efficacy of IntraCoronary Erythropoietin Delivery BEfore Reperfusion-Gauging Infarct Size in Patients with Acute ST-segment Elevation Myocardial Infarction (ICEBERG) |
| URI | https://www.jstage.jst.go.jp/article/ihj/60/2/60_18-035/_article/-char/en https://www.ncbi.nlm.nih.gov/pubmed/30799375 https://www.proquest.com/docview/2230616726 |
| Volume | 60 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| ispartofPNX | International Heart Journal, 2019/03/30, Vol.60(2), pp.255-263 |
| link | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFLa6gRAviDuFgSzBA6gypI5ze-xKtlasG6Kd2J4iJ7FLp6qdehEq_4f_yfElcSsuggderMh1rDTny7n5XBB6JVibJ7QoSaLqXzKRFyTmnkdoIBnzpIgCnSjcG0anF_H7lKWNRtWV1c39V0rDHNBaZc7-A7XrTWECroHmMALVYfwruqeqJoTq4W5yRBa8q2oUqNi4dLExTREmKs0ZOM1UxWRsWocpKK6qfcO1WMi18p6RY74em1ACCa9n1RpOvuniIh9NFVabEtcpVJDBcESWYqxjCtKpMB7e1mADMnJRmkoeeg8Ds7jfTQ_TT8eVA-LKBdI7v6Rqsr1qbf9bEztMPs-1Y3co5nXgD_AqmDZO3HXt2u5PSc3GzupZnUlBel-Nz_dybhFpfR4qzcqvjm-0PAI9wjE_dcDgziFaHZ2zusXSfZYQ6puOFG-Fm_Opac1UyQHT18DinW4zdVNI-CdhE-huOJMvIG5UmmLgRGoVRnB6lh2dn5xko_RitIduUGCG2uzvf6i0BaYUcu0UsE9pS-jC3u_czjtK080rsBvG4vcmkVaNRnfRHWvT4I4B4z3UELP76NbARm08QN8rTOK5xDuYxLuYxBUmscEk_gUmscUTVpjEcE-FSawwiTUmscMkrjGJHSaxwyR-bRH55iE6P0pH3R6x7UFIwZJ4RcJCJFSGoZfnPKCx4CIuuCy4KEJPSND9IplEIgw4LeOonUcC2BGLadn2eFAWeeA_Qvuz-Uw8QTj2ShkEReSXMmdcBrHkjMGl78OWzGdN9LJ6_9m1qQKTKesZqJQBlbJ2nAGVmigxpKnXWC6g14ReRtVg1tY_qeRK4FtNdFBRM7Pf1zKjyj_QDiMaNtFjQ-F6a5DNyrQInv75xmfotvuADtD-arEWz9Hesly_0DiEMe0OfgDMQ9Ny |
| link.rule.ids | 315,782,786,27933,27934 |
| linkProvider | Flying Publisher |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Efficacy+of+IntraCoronary+Erythropoietin+Delivery+BEfore+Reperfusion-Gauging+Infarct+Size+in+Patients+with+Acute+ST-segment+Elevation+Myocardial+Infarction+%28ICEBERG%29&rft.jtitle=International+heart+journal&rft.au=Won-Woo%2C+Seo&rft.au=Jung-Won%2C+Suh&rft.au=Il-Young%2C+Oh&rft.au=Chang-Hwan%2C+Yoon&rft.date=2019-03-30&rft.pub=Japan+Science+and+Technology+Agency&rft.issn=1349-2365&rft.eissn=1349-3299&rft.volume=60&rft.issue=2&rft.spage=255&rft_id=info:doi/10.1536%2Fihj.18-035&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1349-2365&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1349-2365&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1349-2365&client=summon |